Immediate Impact
3 from Science/Nature 56 standout
Citing Papers
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
2025 Standout
Advances in cancer immunotherapy: historical perspectives, current developments, and future directions
2025 Standout
Works of Paul Taylor being referenced
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial
2018
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
2017 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Paul Taylor | 540 | 346 | 87 | 132 | 31 | 871 | |
| M. Paganuzzi | 508 | 321 | 109 | 252 | 37 | 970 | |
| M. Puglisi | 399 | 531 | 110 | 256 | 36 | 973 | |
| Fabio De Vincenzo | 780 | 250 | 39 | 137 | 53 | 1.1k | |
| Wieneke A. Buikhuisen | 606 | 411 | 247 | 188 | 34 | 1.1k | |
| Letizia Gianoncelli | 606 | 230 | 20 | 142 | 29 | 823 | |
| R.-P. Perng | 420 | 522 | 67 | 313 | 46 | 925 | |
| Rafael Sanchez‐Salas | 582 | 300 | 32 | 204 | 33 | 1.0k | |
| Suchita Pakkala | 509 | 670 | 102 | 150 | 32 | 948 | |
| Munehisa Imaizumi | 452 | 376 | 42 | 246 | 40 | 955 | |
| Masayuki Egawa | 389 | 184 | 31 | 324 | 29 | 783 |
All Works
Loading papers...